All Comments by Takaomi Saido

  1. Neutralization of soluble, synaptotoxic amyloid β species by antibodies is epitope specific.
  2. Propagation of tau pathology in a model of early Alzheimer's disease.
  3. Chitinase enzyme activity in CSF is a powerful biomarker of Alzheimer disease.
  4. Tau Protein Phosphorylation in Diverse Brain Areas of Normal and CRH Deficient Mice: Up-Regulation by Stress.
  5. Exercise Engagement as a Moderator of the Effects of APOE Genotype on Amyloid Deposition.
  6. TLR2 is a primary receptor for Alzheimer's amyloid β peptide to trigger neuroinflammatory activation.
  7. Amyloid Imaging with AV45 (18F-florbetapir) in a Cognitively Normal AβPP Duplication Carrier.
  8. A Canine Model to Evaluate Efficacy and Safety of γ-Secretase Inhibitors and Modulators.
  9. Abnormal cognition, sleep, EEG and brain metabolism in a novel knock-in Alzheimer mouse, PLB1.
  10. A novel glycogen synthase kinase-3 inhibitor 2-methyl-5-(3-{4-[(S )-methylsulfinyl]phenyl}-1-benzofuran-5-yl)-1,3,4-oxadiazole decreases tau phosphorylation and ameliorates cognitive deficits in a transgenic model of Alzheimer's disease.
  11. Amyloid-β associated volume loss occurs only in the presence of phospho-tau.
  12. Novel diffusion barrier for axonal retention of Tau in neurons and its failure in neurodegeneration.
  13. Adaptive responses to alloxan-induced mild oxidative stress ameliorate certain tauopathy phenotypes.
  14. Pseudohyperphosphorylation has differential effects on polymerization and function of tau isoforms.
  15. Resolving Controversies on the Path to AD Therapeutics